NANOTHERAPEUTICS
BIOAVAILABLE | EFFECTIVE | SUSTAINED RELEASE
IMPROVING THERAPEUTIC PRECISION AT ATOMIC LEVEL
Therapeutic targeting of pathogens using surface-modified appropriately scaled nanoparticles is a strategy, that permits drug delivery at the organ or even cellular level.
The size of a virus, ranges from about 20 nanometers (nm) up to 400 nm. In other words, the pathogen is a nanoscale object. It makes sense, to tackle its impact on a host with more precision, using therapeutic deliverable agents, within that size range.
One of the most notable applications of nanotechnology in the biomedical sector, is in the area of drug delivery and nano-therapeutics. Nanoparticle-based delivery systems present new opportunities to overcome challenges associated with conventional drug therapies and this makes them particularly useful for consideration in the treatment of viral infections, which are intracellular in nature.
ROLE OF NANOPARTICLES IN DRUG DELIVERY
The premature release of a drug has implications on the treatment of systemic and intracellular infections. Nanoparticles are retained for much longer periods than conventional therapeutics in the body and this retainment enables a slow and sustained release of therapeutic agents. This is important because under conditions of controlled and sustained release, the goal is to ensure, that the drug concentration is maintained within the therapeutic window, thereby also decreasing the possibility of drug resistance.
These characteristics of nanoparticles are relevant in antiviral therapy in which the high dose of a drug is needed and the drugs are often very expensive. Usage of nanoparticulate carriers can reduce the frequency of the drug intake as well as treatment timeframes, thus enhancing the effectiveness of the approved antiviral therapeutics and overcome their limitations, such as low bioavailability.
SOME DESIGN FACTORS
Nanoparticle uptake is an important consideration in the design of nano-therapeutics, because this will have a direct influence on the therapeutic load, and hence the appropriate dose, entering the cells.
Subsequent biodegradation of the nanoparticles is critical determining the sustained release of a drug and subsequent biodistribution profiles. If biodegradation does not occur, the nanoparticle must eventually exit the cell and be excreted from the body. If nanoparticles are too large to undergo renal clearance, they may accumulate in the body. Smaller particles however (< 5 nm), can be excreted in urine.
It is expected that the usage of quantum materials (typically < 20 nm in diameter) with high surface area in antiviral therapeutic processes will have positive effects in the treatment of infectious diseases. These nanoparticles could potentially improve the efficacy of antiviral drugs and reduce the adverse side effects of the drugs on the body.
OUR OFFER
NANOARC specialises in the development and manufacture of high surface area, sub 20 nm particles. We offer them as ligand-free nanopowder, for controlled dosage within therapeutic drugs.
The advantage of such a configuration is that in the absence of ligands, there is ample surface area on the nanoparticles for the addition of the necessary amount of therapeutic molecules. The flexibility in surface functionalisation implies the nanoparticle charge can be modified to facilitate cellular uptake, when dispersed in the appropriate biocompatible medium of choice.
Coupled with the advantages of slow and sustained drug release outlined above, in order to make the drug(s) more bioavailable, there is a potential in lowering the likelihood of adverse side effects. from high drug doses.
In conjunction with nanoparticle manufacture, we offer support through nanotech consultancy services.
PRODUCTS
Click on "BUY" next to the product(s) of interest to pay with a credit card or contact trade@nanoarc.org to request an invoice for payment via bank transfer.
SUBSCRIPTION MODEL : GET DISCOUNTS & FREE SHIPPING OFF ADVANCE PURCHASES below bulk order volumes
QUARTERLY ( 5 % ) | BI-ANNUALLY ( 10 % ) | ANNUALLY ( 15 % )
ZINCENE OXIDE | ATOMICALLY - ARCHITECTURED 2D ZINC OXIDE
NANOARCHITECTURE : Atomically thin sheets (< 1nm)
DIMENSIONS : < 1 nm thickness, up to 2 um lateral width
SURFACE AREA (BET) : 635200 cm²/g
COLOUR : White Powder
APPLICATIONS : Drug carrier in cancer therapy, Anticancer agent, potent antioxidant and an effective adjuvant treatment to chemotherapeutic drugs that cause reproductive dysfunction in males. Increases the therapeutic efficacy of doxorubicin, and reduces doxorubicin gonado-toxic properties.
Nanocarrier sensitive to acidic pH (~ 4.5). Antiviral, Anti-fungal, Antibacterial (average effective dose at < 30 μg/ml), Effective against Bacillus subtilis, Bacillus megaterium, Staphylococcus aureus, Sarcina lutea, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia ( at 5 μg/ml), Pseudomonas vulgaris, Candida albicans, and Aspergillus niger. Reduce mRNA expression of inflammatory cytokines by inhibiting the activation of NF-kB (nuclear factor kappa B cells). Anticorrosion, antibiotic decontamination, UV filtering, prohibit biofilm formation and inhibit hemolysis by hemolysin toxin produced by pathogens.
ATOMICALLY - ARCHITECTURED 0D ZINC OXIDE
NANOARCHITECTURE : < 10 nm spherical nanoparticles
SURFACE AREA (BET) : 415300 cm²/g
BAND GAP : ~ 3.5 eV
COLOUR : White Nanopowder
APPLICATIONS : Drug carrier in cancer therapy, Anticancer agent, potent antioxidant and an effective adjuvant treatment to chemotherapeutic drugs that cause reproductive dysfunction in males. Increases the therapeutic efficacy of doxorubicin, and reduces doxorubicin gonado-toxic properties.
Nanocarrier sensitive to acidic pH (~ 4.5). Antiviral, Anti-fungal, Antibacterial (average effective dose at < 45 μg/ml), Antifouling, Effective against Bacillus subtilis, Bacillus megaterium, Staphylococcus aureus, Sarcina lutea, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia, Pseudomonas vulgaris, Candida albicans, and Aspergillus niger. Reduce mRNA expression of inflammatory cytokines by inhibiting the activation of NF-kB (nuclear factor kappa B cells). Anticorrosion, antibiotic decontamination, UV filtering, prohibit biofilm formation and inhibit hemolysis by hemolysin toxin produced by pathogens.
ZnO in nanoscopic form can interfere with NorA protein, which is developed by bacteria to confer resistance and has pumping activity that mediates the effluxing of hydrophilic fluoroquinolones from a cell. Furthermore, nano-ZnO can interfere with Omf protein, which is responsible for the permeation of quinolone antibiotics into Staphylococcus aureus and Escherichia coli cells.
Can enhance the antibacterial activity of ciprofloxacin.
ATOMICALLY - ARCHITECTURED AURUM
NANOARCHITECTURE : < 10 nm (0.01 μm) Spherical Nanoparticles
COLOUR : Purple-White/Violet Nanopowder
APPLICATIONS: Sensory probes, therapeutic agents, drug delivery in biotechnological and biomedical applications, Hg and Pd removal.
MAGNETENE | ATOMICALLY - ARCHITECTURED 2D MAGNETITE
NANOARCHITECTURE : Atomically Thin Sheets/Flakes ( < 1 nm Thickness)
SURFACE AREA (BET) : 49550 m²/kg
COLOUR : Black/Blackish-Brown Nanopowder
APPLICATIONS : Electromagnetic wave absorption, colour imaging, intracellular delivery of anti-cancer agents.
HAPENE | ATOMICALLY - ARCHITECTURED 2D HYDROXYAPATITE
NANOARCHITECTURE : Atomically-thin 2D material | < 1 nm (< 0.001 μm) thickness
SURFACE AREA (BET) : 70300 m²/kg
COLOUR : White Nanopowder
APPLICATIONS : Implant material, to promote bone growth and repair lesions in tooth enamel. Impact-resistant material for composites, antimicrobial filter material.
ATOMICALLY - ARCHITECTURED CALCIUM HYDROXIDE
NANOARCHITECTURE : < 25 nm Spherical hollow nanoparticles
SURFACE AREA (BET) : 388000 cm²/g
BAND GAP : ~ 5 eV
COLOUR : White Nanopowder
HEAT RESISTANCE : Up to 580 °C (1076 °F)
APPLICATIONS : Drug delivery, phosphate binder, acidity regulator.
View Safety Data Sheet (SDS) HERE